Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Are PCSK9 Inhibitors Ready For “Widespread Use”?

This article was originally published in The Pink Sheet Daily

Executive Summary

Addressing new post hoc analyses of outcomes data, AHA/ACC treatment guidelines chair Neil Stone suggests PCSK9 inhibitors seem on track for an important role in cardiovascular disease, but warns against widespread use until outcomes data from well-powered trials are in.

Advertisement

Related Content

Time, And Price, Are Right To Prescribe Statins To the Masses

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078261

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel